<DOC>
	<DOCNO>NCT02955576</DOCNO>
	<brief_summary>The purpose study evaluate efficacy microneedle patch psoriatic plaque .</brief_summary>
	<brief_title>Microneedle Patch Psoriatic Plaques</brief_title>
	<detailed_description>As novel minimally invasive approach , microneedle-mediated transdermal drug delivery receive increased attention . Microneedle patch effectively penetrate skin barrier stratum corneum create efficient pathway delivery drug . A randomized control trial base split-body plan evaluate efficacy enhance transdermal delivery topical agent hyaluronic acid ( HA ) -fabricated microneedle patch psoriatic plaque . Six psoriatic plaque patient randomize either microneedle HA patch , patch , control group . Patch group plan rule occlusion effect patch . All lesion treat topical agent patch daily 2-week period . The severity psoriasis grate modified PASI score clinical improvement assess % baseline every week . Overall 20 patient 120 psoriatic plaque enrol .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<criteria>Age : old 19 A patient psoriasis A patient symmetrical psoriatic lesion A patient willingness comply study protocol study period capable comply A patient sign informed consent prior participation study understand he/she right withdrawal participation study time without disadvantage Age : low 20 A pregnant lactating patient A patient understand study sign inform consent</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Psoriasis</keyword>
</DOC>